Linked Life Data

4349414

Source:http://linkedlifedata.com/resource/pubmed/id/4349414

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5860
pubmed:dateCreated
1973-6-22
pubmed:abstractText
Eight males were studied during 27 weeks, including two periods of five weeks during which they received clinical doses of sodium amylobarbitone and benzoctamine. Substitution of placebo for either drug caused raised anxiety and impairment of mental concentration. The drugs reduced restlessness during sleep and reduced paradoxical sleep. By the fifth week of sodium amylobarbitone, although sleep was still less restless in the early night it was more restless than normal in the late night.Blood samples were taken half-hourly during sleep by indwelling venous catheter. Plasma growth hormone concentration was little affected during drug administration but rose temporarily after withdrawal. There was a reduction of plasma corticosteroid concentration during sleep throughout administration of the drugs and a rebound above normal during the first withdrawal week.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0007-1447
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
202-5
pubmed:dateRevised
2010-10-26
pubmed:meshHeading
pubmed:year
1973
pubmed:articleTitle
Two anti-anxiety drugs: a psychoneuroendocrine study.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial